Technology

New Studies Validate the Value of Brainomix AI Technology Across US Stroke Networks

Published

2 years ago

July 25, 2024

The studies presented this week at the Society of Neurointerventional Surgery (SNIS) underline the company’s rigorous evidence-based approach to developing and validating novel AI solutions that can help to optimize patient care across stroke networks.

OXFORD, England and CHICAGO, July 25, 2024 /PRNewswire/ — Brainomix, a pioneer in artificial intelligence (AI) imaging solutions, announced new data from studies that were presented this week at the US-based Society of Neurointerventional Surgery’s (SNIS) Annual Meeting in Colorado Springs. The latest research, in collaboration with the Mayo Clinic, West Virginia University, and Boston Medical Center, highlighted some of the cutting-edge, AI-enabled technology that the Oxford-based company has developed within its pipeline for the Brainomix 360 Stroke platform, representing groundbreaking capabilities that will enable physicians to extract maximal value from universally available non-contrast CT scans across stroke networks.

The FDA-cleared Brainomix 360 Stroke platform is powered by state-of-the-art AI algorithms that provide real-time interpretation of brain scans to aid treatment and transfer decisions for stroke patients, with the aim of enabling more patients to receive the right treatment, in the right place, at the right time.

Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said: “The studies presented this week at SNIS symbolize our ongoing commitment to scientific excellence and reflect the successful partnerships that we have forged with leading academic institutions across the United States to jointly explore the frontiers of stroke AI imaging. Together we are identifying exciting opportunities that may expand the capabilities of physicians to better manage stroke patients across all levels of stroke networks with our technology.”

Dr Ansaar Rai, Professor and Chair, Department of Neuroradiology & Neurointerventional Surgery, West Virginia University, said: “The studies presented this week at SNIS highlight the clinical value of the Brainomix 360 Stroke platform, particularly relating to the e-ASPECTS and Triage Stroke algorithms that assess non-contrast CT scans, which are universally available to all stroke centers across the US. The results indicate that these algorithms generate clinically relevant results for frontline stroke physicians that could help them to better manage stroke patients eligible for mechanical thrombectomy across all centers within a network.”

Key studies presented at SNIS included:

“AI Derived Clot Characteristics Predict Recanalization Success in Large Vessel Acute Stroke Patients Undergoing Mechanical Thrombectomy” was a research collaboration between Brainomix and West Virginia University in which baseline non-contrast CT (NCCT) scans from patients with large vessel occlusion (LVO) were analyzed with Brainomix 360 e-ASPECTS to identify hyperdense clots and quantify their length. The results showed that clot biomarkers from NCCT are predictors of successful recanalization and could facilitate the planning of mechanical thrombectomy (MT) procedures.”Large Vessel Occlusion Detection in Acute Ischemic Stroke Using Non-Contrast CT” was a multisite collaboration with the Mayo Clinic, West Virginia University, and Boston Medical Center validating Triage Stroke as a reliable tool for LVO detection. The authors concluded that when coupled with clinical information such as NIHSS, the tool may help centers to identify thrombectomy candidates, especially those with constrained resources and basic imaging.”How Dark Is Too Dark? Using Net-Water Uptake to Predict Futile Recanalization Following Mechanical Thrombectomy” was another multisite collaboration, this one between the Mayo Clinic, West Virginia University and Brainomix. Ischemic core volume and depth of hypoattenuation using Net Water Uptake (NWU) were quantified from baseline CT scans using Brainomix 360 e-ASPECTS, with results showing that NWU extracted automatically from routine imaging may help identify patients at risk of futile recanalization – especially those with large cores.

About Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts

Jeff Wyrtzen, Chief Marketing & Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730

Media enquiries

Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585

Logo: https://mma.prnewswire.com/media/1989193/3856380/Brainomix_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/new-studies-validate-the-value-of-brainomix-ai-technology-across-us-stroke-networks-302206484.html

SOURCE Brainomix

Technology

Function Now Connects to Meta’s Muse, Allowing Members to Bring Their Personal Health Data to the New AI Agent

Published

59 minutes ago

September 9, 2026

Members can securely bring their Function health data into Muse to better understand their health and personalize their AI experience.

AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ — Function today announced that members can securely connect their Function health data to Muse, Meta’s new personal AI agent. Muse joins ChatGPT, Claude, and Perplexity in Function’s growing network of AI connectors, giving members the ability to bring their personal health data into the AI experiences they choose to use.

Muse can use a member’s Function insights as personal context to help them understand their health, build and adapt plans around their goals, track progress, and follow through over time, while members remain in control of their data.

“Your AI should know your biology,” said Jonathan Swerdlin, CEO and Co-founder of Function. “By connecting Function health data to Muse, people can bring a living picture of their health into the AI platforms they use every day. We are entering a world where people understand their bodies in far greater detail and increasingly rely on AI to make decisions. Bringing those together makes AI dramatically more useful.”

How it works

Members authorize the connection from inside Meta, through the same account controls they already use to manage their account data. Once connected, Muse draws on their lab results and clinician-reviewed summaries to inform the goals and tasks a member brings to it.

Ask Muse how a lab result compares to a member’s optimal range before deciding whether to act on itHave Muse build or adjust a plan toward a health goal, using a member’s own Function insights as contextLet Muse flag when it’s time to schedule a member’s next Function lab visit, and follow up until it’s on the calendar

The Function health connector will roll out in the coming weeks. To learn more about Function or become a member, visit www.functionhealth.com.

About Function

Function is on a mission to enable everyone to live 100 healthy years. A groundbreaker in its category, Function has changed the game by making lab testing, MRI and CT, and longitudinal health data accessible, understandable, and actionable—serving millions. Function’s Medical Intelligence Lab™ (MI Lab™) is leveraging a dedicated clinical team to develop a continuous learning system that helps its members see, understand, and act on their biology over time. Members receive access to 160+ lab tests—including biannual testing—for just $365/year, equivalent to $1 per day, covering the heart, hormones, thyroid, liver, kidneys, heavy metal exposures, nutrient levels, inflammation, potential cancer signals, and more. Each member’s results are integrated into an intelligent, personalized interface designed to support powerfully informed decision-making. Function members can also access (for an additional cost) MRI and CT that are designed to see signs of cancer and hundreds of other conditions. Function believes everyone should have the power to own their health.

View original content to download multimedia:https://www.prnewswire.com/news-releases/function-now-connects-to-metas-muse-allowing-members-to-bring-their-personal-health-data-to-the-new-ai-agent-302872964.html

SOURCE Function Health

Technology

Teletrac Navman Appoints Ricardo Buranello as CEO

Published

59 minutes ago

September 9, 2026

Alain Samaha to Continue Serving on Board of Directors

SYDNEY, Sept. 9, 2026 /PRNewswire/ — Teletrac Navman, a leading global provider of intelligent fleet and asset management solutions, today announced that it has named current Chief Financial and Operating Officer Ricardo Buranello as Teletrac Navman’s next Chief Executive Officer, effective October 1, 2026. Mr Buranello succeeds Alain Samaha, who will continue in the CEO role through September 30, 2026, to ensure a seamless transition. Mr Samaha will remain a member of Teletrac Navman’s Board of Directors and continue supporting the Company’s long-term vision and strategic planning.

Mr Buranello is a seasoned executive with more than two decades of international experience across telematics, IoT, and high-growth technology businesses. Having served as Chief Financial and Operating Officer since joining Teletrac Navman, he brings deep financial and operational expertise, a strong strategic orientation, and an intimate knowledge of the business that make him ideally suited to lead the Company into its next chapter. Mr Buranello previously held leadership roles at Telit Cinterion, Siemens and Totvs.

“This represents an ideal time for Teletrac’s next phase of leadership, and we’re confident that Ricardo is the right person for the job,” said Jonathan Olefson, Chairman of the Board at Teletrac Navman. “Ricardo is a proven, mission-oriented leader who understands our business from the inside out. We look forward to what he and the entire team will accomplish.”

“Alain helped transform Teletrac into a global leader in telematics and fleet management solutions. We are grateful for his vision, passion, and many contributions, and look forward to working with him on the Board,” continued Olefson.

Mr Samaha stated, “Leading Teletrac has been one of the great privileges of my professional life. I am proud of what we have done together, and I am equally excited about what lies ahead for Teletrac. Ricardo is the right leader for this moment. His strategic clarity and deep understanding of our business will serve Teletrac, our customers, and our employees well into the future.”

Mr Buranello added, “I am honoured by the trust the Board has placed in me and energised by the opportunities ahead. Our customers, employees, and partners can count on the same dedication to innovation, excellence, and delivering meaningful results that has been at the core of Teletrac since the beginning.”

Under Mr Buranello’s leadership, Teletrac Navman will continue advancing its cloud-based, AI-powered connected mobility platform while building on the growth, stability, and customer focus that have long defined the Company.

About Teletrac Navman

Teletrac Navman empowers the industries that transform and sustain our futures with simple and intelligent solutions that enhance the efficiency, safety, and sustainability of their operation. As a connected mobility platform for industries that manage vehicle and equipment assets, Teletrac Navman simplifies the complex so that its customers can transform the way they work through cloud-based solutions that leverage AI to unlock the power of operational insight. The company operates globally, with offices worldwide and headquarters in Northbrook, IL. For more information visit https://www.teletracnavman.com.au/.

About Respida

Respida is a software-focused private equity firm with decades of combined investing and operating experience. The firm partners with management teams at growth-oriented software and software-enabled companies, bringing hands-on operational rigor and financial discipline to drive growth and build durable market leaders. For more information, visit https://respida.com/.

View original content:https://www.prnewswire.com/apac/news-releases/teletrac-navman-appoints-ricardo-buranello-as-ceo-302872980.html

SOURCE Teletrac Navman

Technology

Coda welcomes Bombay High Court judgment in its favor

Published

59 minutes ago

September 9, 2026

SINGAPORE, Sept. 8, 2026 /PRNewswire/ — Coda welcomed the Bombay High Court’s judgment on 2 September 2026 allowing the appeal by Coda Payments India and setting aside the orders that had kept its bank accounts and payment accounts frozen.

The judgment is a significant and positive outcome for Coda. We have been clear and consistent in our position throughout the proceedings and welcome the Court’s decision.

Coda has cooperated fully with the relevant authorities and respects the legal process. We now look forward to the judgment being implemented expeditiously and in full.

Coda remains committed to meeting all applicable legal and regulatory requirements in every market in which it operates.

The Bombay High Court’s judgment relates to the freeze on Coda Payments India’s bank accounts and payment accounts. Other related proceedings remain ongoing.

About Coda

Coda is a global leader in monetization, distribution, and commerce, trusted by the biggest names in gaming, entertainment, and technology, including Activision, Electronic Arts, Riot Games, Ubisoft, and Moonton. Founded in 2011 and headquartered in Singapore, Coda operates with 670+ employees worldwide, with core hubs in Asia and Europe. Coda combines payments, commerce, distribution, and rewards to drive global revenue growth for brands and publishers.

Coda’s products include Codapay, which provides access to 400+ payment methods across 80+ markets through a single API integration; Coda Webstore, which powers fully customized direct-to-consumer storefronts; Coda Consumer Platforms, including Codashop, Recharge.com, and Startselect.com; Coda Distribution, which extends reach through a network of commerce partners; and Giftcloud, a UK-based rewards business serving enterprise customers across Europe.

Coda is backed by Apis Partners, Insight Partners, Smash Capital, and GIC, and has been named an APAC High Growth Company (2023) by Financial Times, one of Granite Asia’s NextGenTech 30 (2024), a payments leader on Fortune’s Fintech Innovation Asia list (2024), and listed among The Straits Times Fastest Growing Fintechs (2024). For more on Coda, visit coda.co.

Press Contact
Coda:
Liz Adam
VP, Corporate Affairs
liz.adam@coda.co

View original content:https://www.prnewswire.com/apac/news-releases/coda-welcomes-bombay-high-court-judgment-in-its-favor-302872984.html

SOURCE Coda